TickerTalks
Browse all tickers →
TickerTalks›$NUVL
NUNUVL

Nuvalent, Inc.

$NUVL·$9.1B·Biotechnology·Healthcare
$123.960.0%YTD+23.3%1Y+51.0%
Mentions · last 7 days
2026-07-20: 1 posts2026-07-21: 1 posts2026-07-22: 4 posts2026-07-23: 2 posts2026-07-24: 1 posts2026-07-25: 0 posts2026-07-26: 3 posts12+13%
Price updated 14m ago·X counts updated 23h ago
NUNUVL
$NUVLNuvalent, Inc.
$123.960.00%12 posts+13%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $NUVL, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-07-25

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Nuvalent is being taken out by GSK at $124/share — tender offer completed July 15 and the tape is coiled just below the deal price with Kahn Swick fair-price investigations.

Nuvalent Inc. is a US-listed clinical-stage oncology biotech developing selective ROS1 and ALK inhibitors targeting resistance mutations in non-small-cell lung cancer. Shares are up 23% year-to-date and 51% over twelve months at $123.96 above the 50-day and 200-day MAs, and August 6 Q2 earnings is the near-term catalyst.

  • The GSK $124/share tender-offer completion is the defining event: the July 15 8-K disclosed GSK plc completed its acquisition via a tender offer at $124.00 per share (offer expiring July 14), following the June 9 Merger Agreement — a specific merger-arb setup where the tape at $123.96 sits essentially at the deal price.
  • Multiple Kahn Swick and Brodsky & Smith fair-price investigations are the specific overhang: the July 13 Kahn Swick investigation and the July 16 and July 21 Brodsky & Smith investigations — a wall of shareholder-side legal-noise that historically extends but rarely materially changes deal outcomes.
  • The $10.6B deal represents a 2.5x peak-revenue multiple: sentiment cites GSK acquired Nuvalent at $10.6B representing a 2.5x peak-revenue multiple on $4B projected sales, with two new lung-cancer drugs expected to hit the market later this year — a specific benchmark that supports the pipeline value.
  • Revenue is genuinely zero: Q1 2026 revenue was $0M with continued clinical-stage operating losses (-$1.44 EPS estimate for Q2) — a pre-commercial biotech where the equity value derives from the GSK deal consideration, not from trailing operations.

August 6 Q2 2026 earnings is pro-forma commentary as the GSK acquisition has effectively closed — the tape from here is bond-like return to the $124 deal price with residual arb-spread reflecting closing-mechanic risk; the deciding developments are any specific Kahn Swick/Brodsky settlement, the delisting timeline, and any competing-bid speculation (increasingly unlikely with GSK tender expired).

Agrees with X sentimentX is bullish on the GSK/Nuvalent deal framing it as the M&A benchmark for ABVX at a $122 BO price assuming similar peak-revenue economics, and I agree — the $10.6B / 2.5x peak-revenue multiple is a legitimate transaction reference, and the July 15 tender-offer completion at $124 is a specific fixing event; the fair-price investigations are typical M&A noise unlikely to change the outcome.

What to watch: August 6 Q2 2026 earnings and delisting timeline — Kahn Swick/Brodsky-Smith settlement progression, delisting mechanics, and any residual arb-spread; competing-bid speculation is essentially closed.

On the calendar: 2026-08-06 — Q2 2026 earnings

merger arbitrageclinical stage biotechclass action investigation

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment6 posts analyzed · as of 2026-06-19

GSK acquired Nuvalent for $10.6B representing a 2.5x peak-revenue multiple on $4B projected sales, with two new lung-cancer drugs expected to hit the market later this year. Authors frame the deal as the M&A benchmark for ABVX at a $122 BO price assuming similar peak-revenue economics.

Read the AI verdict + X sentiment for $NUVL

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage oncology biotech developing next-generation ROS1 and ALK inhibitors for lung cancer patients with acquired resistance.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $NUVL.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $NUVL

Partial — Clinical-stage oncology biotech developing next-generation ROS1 and ALK inhibitors for lung cancer patients with acquired resistance; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+10.9%YTD
+38.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-21.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-35.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-42.8%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-1.39$-1.35-3.0%
Q4 2025Feb 26, 2026$-1.29$-1.48+12.8%
Q3 2025Oct 30, 2025$-1.70$-1.39-22.3%
Q2 2025Aug 7, 2025$-1.31$-1.27-3.1%
Next earningsThu, Aug 6·consensus EPS $-1.44

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-1.39$-92.4M
Q4 FY25$0———$-1.58$-73.3M
Q3 FY25$0———$-1.70$-70.5M
Q2 FY25$0———$-1.39$-76.6M

Forward consensus

5-year forecast · up to 16 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$11.2M$627K – $34.7M-$5.65-$6.26 – -$5.0511
FY27$187.8M$116.4M – $253.4M-$4.35-$6.23 – -$3.1011
FY28$527.5M$527.5M – $527.5M-$1.30-$5.42 – $4.0916
FY29$940.7M$557.8M – $1.5B$2.82$1.33 – $4.9115
FY30$1.3B$753.9M – $2.0B$5.13$2.42 – $8.9515

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.—Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.100%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+9.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+19.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 49.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.β1.145-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 9Henry E. PelishChief Scientific Officer2.1K sh$261KSellJul 6Porter James RichardCEO30.0K sh$3.7MSellJul 1Darlene NociChief Development Officer23.0K sh$2.8MSellJul 1Alexandra BalcomCFO11.4K sh$1.4MSellJun 29Darlene NociChief Development Officer5.5K sh$679KSellJun 9Darlene NociChief Development Officer20.0K sh$2.5MSellJun 8Porter James RichardCEO30.0K sh$2.7MSellMay 28Darlene NociChief Development Officer5.5K sh$593KSellMay 28Miller Deborah AnnChief Legal Officer5.5K sh$593KSellMay 4Porter James RichardCEO10.5K sh$1.1M
1–10 of 14
+ 39 other (13 exempts · 11 awards · 8 returns · 7 tenders) in window

See when $NUVL insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KAcquisition completedJul 158-K — Item 2.01: Acquisition completed · Item 3.01: Listing / delisting notice · Item 3.03 · Item 5.01: Change in control · Item 5.02: Officer or director change · Item 5.03: Charter amendment
AI summary

GSK plc completed its acquisition of Nuvation Bio (NUVL) via a tender offer at $124.00 per share, with the offer expiring at one minute after 11:59 PM Eastern Time on July 14, 2026. A total of 72,518,967 shares were tendered, representing approximately 91.3% of outstanding shares (67,083,713 Class A and 5,435,254 Class B shares). The offer was not extended, and GSK will proceed with a short-form merger to acquire remaining shares. This transformative deal integrates Nuvation Bio's oncology pipeline into GSK's portfolio. Multiple 8-K items were triggered, including completion of acquisition (2.01), changes in control (5.01), and changes to board/management (5.02).

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
AI summary

Nuvalent, Inc. held its 2026 Annual Meeting on June 16, 2026, with 71.19M of ~73.5M eligible shares represented (96.8% turnout). Stockholders elected two Class II directors for three-year terms through 2029: Michael L. Meyers, M.D., Ph.D. (57.6M for / 13.1M withheld, ~18% withhold) and Ron Squarer (70.6M for / 90K withheld, near-unanimous). KPMG LLP was ratified as auditor and executive compensation was approved on an advisory basis. Routine annual meeting; Meyers' elevated withhold rate (~18%) may reflect proxy advisory guidance on specific governance concerns.

8-KMaterial agreementJun 98-K — Item 1.01: Material agreement · Item 7.01: Press release / Reg FD
AI summary

Nuvalent, Inc. entered into a Merger Agreement on June 9, 2026, with GlaxoSmithKline LLC (a GSK plc subsidiary) under which GSK's acquisition vehicle Harmony Row Acquisition Co. will commence a tender offer to purchase all outstanding Nuvalent Class A and Class B shares at $124.00 per share in cash, with any remaining shares acquired through a back-end merger. The obligation to close is conditioned on customary tender conditions (minimum tender threshold, regulatory approvals). GSK plc is the ultimate parent guarantor. At $124.00 per share, this is a transformative cash acquisition of a clinical-stage ROS1/ALK oncology company by a major pharmaceutical acquirer — highly material and typically represents a significant premium to pre-announcement trading prices.

3New insider — initial holdingsMar 203
+ 35 other (6 S-8 POSs · 5 13Gs · 4 SC TO-T/As · 3 SC 14D9/As) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Fifth Third Bancorp Acquires New Holdings in Nuvalent, Inc. $NUVLdefenseworld.net·6d agoBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)globenewswire.com·6d agoBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AtaiBeckley Inc. (Nasdaq – ATAI), Distribution Solutions Group, Inc. (Nasdaq – DSGR), Cross Country Healthcare, Inc. (Nasdaq – CCRN), Nuvalent, Inc. (Nasdaq – NUVL)globenewswire.com·11d agoNuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVLgurufocus.com·14d agoNuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVLbusinesswire.com·14d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$AURA$SLS$ABVX$MRNA$ALLO$IBRX$ABCL$IOVA
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport